Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
27,748,559
-
Total 13F shares
-
13,622,837
-
Share change
-
-1,996,769
-
Total reported value
-
$351,333,277
-
Put/Call ratio
-
3.3%
-
Price per share
-
$25.79
-
Number of holders
-
60
-
Value change
-
+$19,238,054
-
Number of buys
-
32
-
Number of sells
-
24
Institutional Holders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) as of Q3 2025
As of 30 Sep 2025,
RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) was held by
60 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,622,837 shares.
The largest 10 holders included
TCG Crossover Management, LLC, Foresite Capital Management VI LLC, RTW INVESTMENTS, LP, ORBIMED ADVISORS LLC, BOONE CAPITAL MANAGEMENT LLC, Deep Track Capital, LP, VANGUARD GROUP INC, Nantahala Capital Management, LLC, Ikarian Capital, LLC, and Siren, L.L.C..
This page lists
60
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.